Genetic Testing in Diabetes Mellitus: A Clinical Guide to Monogenic Diabetes

Genetic Diagnosis of Endocrine Disorders

Volumn , Issue , 2010, Pages 17-25

  Philipson, Louis H ^a   Murphy, Rinki ^b   Ellard, Sian ^c   Hattersley, Andrew T ^c   Støy, Julie ^d   Greeley, Siri A ^a   Bell, Graeme I ^a   Polonsky, Kenneth S ^e  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c PENINSULA MEDICAL SCHOOL   (United Kingdom)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79961073434     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374430-2.00002-X     Document Type: Chapter

References (50)

1. Fajans S.S., Bell G.I., Polonsky K.S. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N. Engl. J. Med. 2001, 345:971-980.
2. Hattersley A., Bruining J., Shield J., et al. ISPAD Clinical Practice Consensus Guidelines 2006-2007. The diagnosis and management of monogenic diabetes in children. Pediatr Diabetes 2006, 7:352-360.
3. Aguilar-Bryan L., Bryan J. Neonatal diabetes mellitus. Endocr. Rev. 2008, 29:265-291.
4. Ellard S., Bellanne-Chantelot C., Hattersley A.T. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 2008, 51:546-553.
5. Murphy R., Ellard S., Hattersley A.T. Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat. Clin. Pract. Endocrinol. Metab. 2008, 4:200-213.
6. Vaxillaire M., Froguel P. Monogenic diabetes in the young, pharmacogenetics and relevance to multifactorial forms of type 2 diabetes. Endocr. Rev. 2008, 29:254-264.
7. Tager H., Given B., Baldwin D., et al. A structurally abnormal insulin causing human diabetes. Nature 1979, 281:122-125.
8. D.F. Steiner, H.S. Tager, K. Nanjo, et al., Familial syndromes of hyperproinsulinemia and hyperinsulinemia with mild diabetes, in: The Metabolic Basis of Inherited Disease, seventh ed, vol. 1, McGraw-Hill, New York, 1995, pp. 897-904.
9. Stoy J., Edghill E.L., Flanagan S.E., et al. Insulin gene mutations as a cause of permanent neonatal diabetes. Proc. Natl. Acad. Sci. USA 2007, 104:15040-15044.
10. Lindgren C.M., McCarthy M.I. Mechanisms of disease: genetic insights into the etiology of type 2 diabetes and obesity. Nat. Clin. Pract. Endocrinol. Metab. 2008, 4:156-163.
11. US Centers for Disease Control and Prevention National diabetes fact sheet, 2007 2008, CDC, US Dept. of Health & Human Services, Atlanta, GA.
12. Temple I.K., Shield J.P. Transient neonatal diabetes, a disorder of imprinting. J. Med. Genet. 2002, 39:872-875.
13. Raeder H., Johansson S., Holm P.I., et al. Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction. Nat. Genet. 2006, 38:54-62.
14. Gloyn A.L., Pearson E.R., AntcliffJ.F., et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N. Engl. J. Med. 2004, 350:1838-1849.
15. Pearson E.R., Flechtner I., Njolstad P.R., et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N. Engl. J. Med. 2006, 355:467-477.
16. Gloyn A.L., Ellard S. Defining the genetic aetiology of monogenic diabetes can improve treatment. Exp. Opin. Pharmacother. 2006, 7:1759-1767.
17. Tattersall R.B., Fajans S.S. A difference between the inheritance of classical juvenile-onset and maturity-onset type diabetes of young people. Diabetes 1975, 24:44-53.
18. Fajans S.S. Heterogeneity of insulin responses in maturity-onset type diabetes (MOD) and in maturity-onset type diabetes of young people (MODY). Adv. Exp. Med. Biol. 1979, 119:171-175.
19. Fajans S.S. Maturity-onset diabetes of the young (MODY). Diabetes Metab. Rev. 1989, 5:579-606.
20. Bellanne-Chantelot C., Clauin S., Chauveau D., et al. Large genomic rearrangements in the hepatocyte nuclear factor-1beta (TCF2) gene are the most frequent cause of maturity-onset diabetes of the young type 5. Diabetes 2005, 54:3126-3132.
21. Ellard S., Thomas K., Edghill E.L., et al. Partial and whole gene deletion mutations of the GCK and HNF1A genes in maturity-onset diabetes of the young. Diabetologia 2007, 50:2313-2317.
22. Feigerlova E., Pruhova S., Dittertova L., et al. Aetiological heterogeneity of asymptomatic hyperglycaemia in children and adolescents. Eur. J. Pediatr. 2006, 165:446-452.
23. Froguel P., Zouali H., Vionnet N., et al. Familial hyperglycemia due to mutations in glucokinase - definition of a subtype of diabetes mellitus. New Engl. J. Med. 1993, 328:697-702.
24. Thomson K.L., Gloyn A.L., Colclough K., et al. Identification of 21 novel glucokinase (GCK) mutations in UK and European Caucasians with maturity-onset diabetes of the young (MODY). Hum. Mutat. 2003, 22:417.
25. Velho G., Froguel P., Gloyn A., et al. Maturity onset diabetes of the young type 2. Glucokinase and Glycemic Disease 2004, 42-64. Karger, Basel. F.M. Matschinsky, M.A. Magnuson (Eds.).
26. Matschinsky F.M., Magnuson M.A., Zelent D., et al. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes 2006, 55:1-12.
27. Spyer G., Hattersley A.T., Sykes J.E., et al. Influence of maternal and fetal glucokinase mutations in gestational diabetes. Am. J. Obstet. Gynecol. 2001, 185:240-241.
28. Shields B.M., Spyer G., Slingerland A.S., et al. Mutations in the glucokinase gene of the fetus result in reduced placental weight. Diabetes Care 2008, 31:753-757.
29. Edghill E.L., Bingham C., Ellard S., et al. Mutations in hepatocyte nuclear factor-1beta and their related phenotypes. J. Med. Genet. 2006, 43:84-90.
30. Edghill E.L., Dix R.J., Flanagan S.E., et al. HLA genotyping supports a nonautoimmune etiology in patients diagnosed with diabetes under the age of 6 months. Diabetes 2006, 55:1895-1898.
31. Ellard S., Flanagan S.E., Girard C.A., et al. Permanent neonatal diabetes caused by dominant, recessive, or compound heterozygous SUR1 mutations with opposite functional effects. Am. J. Hum. Genet. 2007, 81:375-382.
32. Mackay D.J., Callaway J.L., Marks S.M., et al. Hypomethylation of multiple imprinted loci in individuals with transient neonatal diabetes is associated with mutations in ZFP57. Nat. Genet. 2008, 40(8):949-951.
33. Babenko A.P., Polak M., Cave H., et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N. Engl. J. Med. 2006, 355:456-466.
34. +) channels. Pflugers Arch. 2007, 453:703-718.
35. Molven A., Ringdal M., Nordbo A.M., et al. Mutations in the insulin gene can cause MODY and autoantibody-negative type 1 diabetes. Diabetes 2008, 57:1131-1135.
36. Polak M., Dechaume A., Cave H., et al. Heterozygous missense mutations in the insulin gene are linked to permanent diabetes appearing in the neonatal period or in early infancy: a report from the French ND (Neonatal Diabetes) Study Group. Diabetes 2008, 57:1115-1119.
37. Stoy J., Greeley S.A., Paz V.P., et al. United States Neonatal Diabetes Working Group Diagnosis and treatment of neonatal diabetes: a United States experience. Pediatr Diabetes 2008, 9(5):450-459.
38. Redondo M.J., Eisenbarth G.S. Genetic control of autoimmunity in Type I diabetes and associated disorders. Diabetologia 2002, 45:605-622.
39. Ehrmann D.A. Genetic contributions to glucose intolerance in polycystic ovary syndrome. Reprod. Biomed. Online 2004, 9:28-34.
40. Ehrmann D.A., Liljenquist D.R., Kasza K., et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2006, 91:48-53.
41. Taylor S.I., Arioglu E. Syndromes associated with insulin resistance and acanthosis nigricans. J. Basic. Clin. Physiol. Pharmacol. 1998, 9:419-439.
42. Musso C., Cochran E., Moran S.A., et al. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. Medicine (Baltimore) 2004, 83:209-222.
43. Caron M., Auclair M., Donadille B., et al. Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence. Cell Death Differ. 2007, 14:1759-1767.
44. Decaudain A., Vantyghem M.C., Guerci B., et al. New metabolic phenotypes in laminopathies: LMNA mutations in patients with severe metabolic syndrome. J. Clin. Endocrinol. Metab. 2007, 92:4835-4844.
45. Moreau F., Boullu-Sanchis S., Vigouroux C., et al. Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a case report. Diabetes Metab. 2007, 33:385-389.
46. Vantyghem M.C., Faivre-Defrance F., Marcelli-Tourvieille S., et al. Familial partial lipodystrophy due to the LMNA R482W mutation with multinodular goitre, extrapyramidal syndrome and primary hyperaldosteronism. Clin. Endocrinol. (Oxf.) 2007, 67:247-249.
47. Barroso I., Gurnell M., Crowley V.E., et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999, 402:880-883.
48. Meirhaeghe A., Amouyel P. Impact of genetic variation of PPARgamma in humans. Mol. Genet. Metab. 2004, 83:93-102.
49. Guettier J.M., Park J.Y., Cochran E.K., et al. Leptin therapy for partial lipodystrophy linked to a PPAR-gamma mutation. Clin. Endocrinol. (Oxf.) 2008, 68:547-554.
50. Edghill E.L., Flanagan S.E., Patch A.M., et al. Insulin mutation screening in 1,044 patients with diabetes: mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood. Diabetes 2008, 57:1034-1042.